Drs. Cices and Ungar discuss how they personalize biologic therapy for atopic dermatitis, especially in older adults, young patients, and those with complex comorbidities. They compare targeted biologics and JAK inhibitors, highlighting options like dupilumab, lebrikizumab, tralokinumab, and nemolizumab, and emphasize shared decision-making to align treatment with each patient’s lifestyle, comorbidities, and priorities.

Drs. Griffiths and Chase explain type 2–high asthma as a multisystem inflammatory disease that often coexists with conditions like allergic rhinitis, sinus disease with polyps, eczema, food allergies, and eosinophilic esophagitis. They emphasize the importance of recognizing type 2–high patterns through history and biomarkers; they also discuss the roles of multidisciplinary care, optimized inhaler use, reduced steroid exposure, and targeted biologic therapy when asthma remains uncontrolled.

This episode examines new evidence comparing omalizumab with multiallergen oral immunotherapy for multiple food allergies, finding that omalizumab may offer better tolerability and treatment completion. It also reviews the ICECAP trial, which found no neurologic benefit from extending hypothermia after out-of-hospital cardiac arrest, and the SOLARIS trial, in which high-dose vitamin D3 did not improve outcomes in metastatic colorectal cancer.

Drs. Denny and Berger review how to optimize continuity of care and secondary stroke prevention as patients transition from hospital to home. They emphasize multidisciplinary outpatient stroke care, psychosocial needs, and safe return to community roles.

Drs. Owens and de Feria discuss strategies to identify latent LVOTO in hypertrophic cardiomyopathy and avoid misclassifying patients as non‑obstructive. They review diagnostic echo maneuvers and outline evolving pharmacologic and interventional treatment pathways.

This episode reviews four clinically relevant studies: emerging NaV1.8 inhibitors as promising non-opioid therapies for acute pain, a once-weekly oral HIV maintenance regimen demonstrating noninferiority to daily treatment, evidence supporting abbreviated dual antithrombotic therapy after PCI in selected patients with atrial fibrillation, and a meta-analysis showing limited benefit of oral antihistamines for atopic dermatitis. Together, these studies highlight evolving evidence that may influence prescribing practices across multiple specialties

Drs. Wise and Stohl discuss emerging cell therapies for refractory lupus, focusing on the CASTLE trial and its promising early results in resetting the immune system and achieving treatment-free remission. They balance enthusiasm with caution, stressing unknown long-term safety, practical, and logistical barriers, and the need to avoid overselling these therapies as a near-term cure.

Drs. Buse and Bonakdar discuss how migraine is deeply intertwined with mental health conditions such as depression and anxiety, forming a powerful “multimorbidity” cluster that can intensify pain, disability, and stigma. By combining compassionate, stigma-free communication with evidence-based tools—from simple screening questions (such as PHQ-9, GAD-7, and anhedonia prompts) to pharmacologic and behavioral therapies—clinicians can meaningfully improve both migraine and mood outcomes for their patients.

Drs. Alexander and Witteles discuss emerging data on transthyretin amyloid cardiomyopathy therapies, emphasizing early initiation of disease-modifying treatment and the prognostic value of functional measures such as the six-minute walk test. They also highlight observational evidence that aggressive cardiometabolic management, including use of newer antidiabetic agents, may further reduce residual cardiovascular risk in patients with ATTR-CM and diabetes.

Drs. Montesi and Martinez explore how to define and monitor PPF, especially in non-IPF ILD. They describe advances in recognizing progression and the use of antifibrotic therapy, while also highlighting ongoing controversy over exact criteria and emphasizing the need to combine symptoms, lung function (FVC, DLCO), and CT imaging for careful, regular follow-up.